Q3 2024 Summary
Published Feb 3, 2025, 6:13 PM UTC- Ashland's innovations in Personal Care are gaining momentum, particularly with new products like transformed vegetable oil (TVO), and obtaining registration to sell in China opens the door for significant growth opportunities in this high-margin segment.
- In Specialty Additives, Ashland is expanding beyond its core rheology offerings, engaging with customers on exciting new innovations, which positions the company for future growth in this area.
- The company's 'globalize' business lines, representing 10% of Ashland's portfolio, are experiencing double-digit growth with higher margins, and Ashland aims to continue investing in these asset-light businesses to drive further profitable growth.
- Ashland is experiencing slower-than-expected demand recovery in its Specialty Additives segment, particularly in the coatings market , with North America and Europe not showing the strength anticipated, and China's market slowing down significantly. This could result in lower volume growth and potential margin pressure due to increased competition and deflationary trends in raw materials.
- In the Life Sciences segment, Ashland has faced market share loss in its VP&D pharma business, especially in Europe, due to aggressive pricing by competitors. The company has reduced its guidance and is uncertain about the timing and extent of recovering this lost share, which could impact future earnings.
- Ashland has lowered its adjusted EBITDA guidance for fiscal 2024 to $465 million to $475 million, down from the previous guidance of $470 million to $500 million , citing weaker performance in VP&D pharma and slower growth in Specialty Additives. This reduction in guidance signals potential challenges in achieving near-term growth and profitability targets.
-
VP&D Impact on EBITDA Guidance
Q: How does VP&D share loss affect EBITDA guidance?
A: The VP&D share loss has led us to reduce our EBITDA guidance for 2024 to $465 million to $475 million , down from the prior midpoint of $485 million. The share loss, combined with aggressive pricing from competitors, particularly in Europe and China, impacted sales by $14 million in Q3. We are managing the balance between pricing and volume to regain share without eroding margins. -
Recovery in VP&D Business
Q: Will you recover lost VP&D volume?
A: We are negotiating with customers and expect volumes to return in Q1 and Q2 of next year. The timing depends on contract negotiations, and while we aim to regain volume, we're cautious about the balance between price and volume to maintain profitability. -
Cost-Saving Measures in VP&D
Q: Are you taking cost-saving actions in VP&D?
A: Yes, we're implementing cost and productivity initiatives across our entire VP&D supply chain, focusing on our plants in Calvert City and Texas City. We're also managing product mix to strengthen our leadership position in quality, reliability, and cost. -
Fiscal 2025 EBITDA Outlook
Q: What impacts fiscal 2025 EBITDA outlook?
A: Two factors: how we manage the VP&D situation, which may be slightly lower than previously thought, and the dynamic in China affecting overall market recovery. Everything else remains unchanged, and we're managing these issues proactively. -
Coatings Demand Slowdown
Q: Which markets are seeing a downturn?
A: Mostly in Specialty Additives, especially coatings. In North America and Europe, growth hasn't met expectations, and China has slowed significantly. We're monitoring these developments as they impact demand. -
Personal Care Performance
Q: How is Personal Care performing?
A: Personal Care volumes have picked up, benefiting from consumer shifts in spending. We're seeing double-digit growth across skin, hair, and oral care segments. China is performing well for us, particularly with local companies. -
Portfolio Optimization Progress
Q: How is portfolio optimization progressing?
A: It's moving very well; we've implemented most changes in CMC, MC, and HEC plants. We expect the impact to be EBITDA-neutral through 2025. We're repurposing assets to support new novel cellulosics, offering exciting growth opportunities. -
Specialty Additives Operating Income Improvement
Q: Why did Specialty Additives income improve from $10M to $22M?
A: Primarily due to increased production volumes and better plant operations in Q3 versus Q2. Higher absorption and higher sales volume contributed to the improvement. -
Cellulosics vs. VP&D in Life Sciences
Q: Why is cellulosics performing better than VP&D?
A: The cellulosics market is stable and growing, with strong innovation in Klucel and Benecel products. The VP&D issues are more about competitive dynamics, while cellulosics benefit from a healthy market and product portfolio. -
Volume Growth Expectations
Q: What are your volume growth expectations?
A: For Q4, we expect mid-single-digit organic volume growth. This excludes optimization impacts. As we return to normal plant operations, we anticipate more typical volumes without assuming market growth.